Skip to content
Screener

Innoviva, Inc. INVA Stock-Based Comp

Stock-Based Comp at other companies

Pfizer logo
PfizerPFE
$272M+60.0%
Merck & Co. logo
Merck & Co.MRK
$298M+38.0%
AbbVie logo
AbbVieABBV
$444M+8.3%
Insmed logo
InsmedINSM
$41.25M-4.0%
Savara logo
SavaraSVRA
$7.77M+191%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$5.49M+142%

Other financials

Income statement

See full
Revenue$119.6M+19.3%
Gross profit$90.6M+9.0%
Operating income$50.9M+4.3%
Net income-$83.4M-231%
EPS (diluted)-$1.14-248%

Balance sheet

See full
Cash & equivalents$570.4M+43.5%
Total debt$269.7M-40.2%
Total equity$1.2B
Total assets$1.7B+27.7%

Cash flow

See full
Operating cash flow$52.0M+17.9%
CapEx$429.0K
Free cash flow$51.5M+16.9%

Valuation

See full
Market cap$1.49B+20.6%
Enterprise value$1.19B-7.6%
P/E4.2×-27.8×
P/S3.4×+0.1×

Profitability

See full
Gross margin72.2%-10.9pp
Operating margin36.9%-10.7pp
Net margin81.2%+70.8pp
FCF margin43.1%-11.1pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio16×+13.4×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:26 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335235
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Amortization of capitalized fees and depreciation of property and equipment7,0116,976
Amortization of acquired intangible assets13,18013,022
Inventory fair value step-up adjustment included in cost of products sold1,998625
Stock-based compensation7,3104,569
Amortization of debt discount and issuance costs7231,078
Changes in fair values of equity method investments, net(25,816)467
Changes in fair values of equity and long-term investments, net(4,422)54,019
Other non-cash items1,223423

Item 1. Financial Statements

FAQ

What is Innoviva, Inc.'s stock-based comp?
Innoviva, Inc. (INVA) reported stock-based comp of $4.74M in Q2 2026.
How has Innoviva, Inc.'s stock-based comp changed year-over-year?
Innoviva, Inc.'s stock-based comp increased by 95.8% year-over-year, from $2.42M to $4.74M.
What is the long-term trend for Innoviva, Inc.'s stock-based comp?
Over 4 years (2021 to 2025), Innoviva, Inc.'s stock-based comp has grown at a 47.1% compound annual growth rate (CAGR), from $2.02M to $9.45M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about Innoviva, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude